A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

被引:73
作者
Park, YH [1 ]
Ryoo, BY [1 ]
Choi, SJ [1 ]
Kim, HT [1 ]
机构
[1] Korea Inst Radiol & Med Sci, Dept Internal Med, Div Haematol & Oncol, Seoul 139706, South Korea
关键词
capecitabine; docetaxel; advanced gastric cancer;
D O I
10.1038/sj.bjc.6601724
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Capecitabine and docetaxel have considerable single-agent activity in gastric cancer with distinct mechanisms of action and no overlap of key toxicities. A synergistic interaction between these two drugs is mediated by taxane-induced upregulation of thymidine phosphorylase. We investigated the activity and the feasibility of capecitabine and docetaxel combination chemotherapy in patients with previously untreated advanced gastric cancer (AGC). From September 2001 to March 2003, 42 patients with AGC received 21-day cycles of oral capecitabine (1250 mg m(-2) twice daily on days 1-14) and docetaxel (75 mg m(-2) i.v. on day 1). The patients received a total of 164 cycles of chemotherapy. The median age was 53.5 years (range 33-73 years). The overall response rate in the 38 efficacy-evaluable patients was 60% (95% confidence interval, 45-74%). The median progression-free survival was 5.2 months (range, 1.0-15 + months) and the median overall survival was 10.5 months (range, 2.9-23.7 + months). The most common grade 3/4 adverse events were hand-foot syndrome (HFS: G3 50%), neutropenia (15%) and leucopenia (12%). Further studies of this combination are clearly warranted, albeit with lower doses of both agents (1000 mg m(-2) twice daily and 60 mg m(-2)) to reduce the rate of HFS and onycholysis.
引用
收藏
页码:1329 / 1333
页数:5
相关论文
共 29 条
  • [21] Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer
    Ridwelski, K
    Gebauer, T
    Fahlke, J
    Kröning, H
    Kettner, E
    Meyer, F
    Eichelmann, K
    Lippert, H
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (01) : 47 - 51
  • [22] Sawada N, 1998, CLIN CANCER RES, V4, P1013
  • [23] Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
    Schüller, J
    Cassidy, J
    Dumont, E
    Roos, B
    Durston, S
    Banken, L
    Utoh, M
    Mori, K
    Weidekamm, E
    Reigner, B
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (04) : 291 - 297
  • [24] Taguchi T, 1998, Gan To Kagaku Ryoho, V25, P1915
  • [25] TEBBUTT N, 2002, P AM SOC CLIN ONCOL, V21
  • [26] Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion
    Thuss-Patience, PC
    Kretzschmar, A
    Krenn, V
    Dörken, B
    Reichardt, P
    [J]. ONKOLOGIE, 2003, 26 (01): : 63 - 65
  • [27] Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials
    Twelves, C
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S15 - S20
  • [28] Van Cutsem E., 2003, EJC Supplements, V1, pS20, DOI 10.1016/S1359-6349(03)90086-3
  • [29] Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
    Van Cutsem, E
    Twelves, C
    Cassidy, J
    Allman, D
    Bajetta, E
    Boyer, M
    Bugat, R
    Findlay, M
    Frings, S
    Jahn, M
    McKendrick, J
    Osterwalder, B
    Perez-Manga, G
    Rosso, R
    Rougier, P
    Schmiegel, WH
    Seitz, JF
    Thompson, P
    Vieitez, JM
    Weitzel, C
    Harper, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (21) : 4097 - 4106